Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Cazzola

Showing results (631-640 of 645) with videos related to

Pageof 65
Sort By:
Blood|November 2, 2022
Germ line DDX41 mutations define a unique subtype of myeloid neoplasmsHideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, et al.
Blood|September 21, 2022
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemiaEric J Duncavage, Adam Bagg, Robert P Hasserjian, et al.
The New England Journal of Medicine|January 9, 2020
Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesPierre Fenaux, Uwe Platzbecker, Ghulam J Mufti, et al.
Current Pharmaceutical Design|March 20, 2014
A systems medicine clinical platform for understanding and managing non- communicable diseasesAlfredo Cesario, Charles Auffray, Alvar Agusti, et al.
Cancer Cell|May 20, 2014
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivoPetter S Woll, Una Kjällquist, Onima Chowdhury, et al.
The New England Journal of Medicine|July 12, 2013
Retinoic acid and arsenic trioxide for acute promyelocytic leukemiaFrancesco Lo-Coco, Giuseppe Avvisati, Marco Vignetti, et al.
Nature Communications|April 8, 2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasmsWilliam Tapper, Amy V Jones, Robert Kralovics, et al.
Leukemia|January 13, 2019
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroupsDetlef Haase, Kristen E Stevenson, Donna Neuberg, et al.
Leukemia & Lymphoma|August 25, 2012
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working GroupArjan A van de Loosdrecht, Robin Ireland, Wolfgang Kern, et al.
Blood|April 30, 2024
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromesMaria Sirenko, Elsa Bernard, Maria Creignou, et al.
Pageof 65

Showing results (631-640 of 645) with videos related to

Sort By:
Pageof 65
Blood|November 2, 2022
Germ line DDX41 mutations define a unique subtype of myeloid neoplasmsHideki Makishima, Ryunosuke Saiki, Yasuhito Nannya, et al.
Blood|September 21, 2022
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemiaEric J Duncavage, Adam Bagg, Robert P Hasserjian, et al.
The New England Journal of Medicine|January 9, 2020
Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesPierre Fenaux, Uwe Platzbecker, Ghulam J Mufti, et al.
Current Pharmaceutical Design|March 20, 2014
A systems medicine clinical platform for understanding and managing non- communicable diseasesAlfredo Cesario, Charles Auffray, Alvar Agusti, et al.
Cancer Cell|May 20, 2014
Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivoPetter S Woll, Una Kjällquist, Onima Chowdhury, et al.
The New England Journal of Medicine|July 12, 2013
Retinoic acid and arsenic trioxide for acute promyelocytic leukemiaFrancesco Lo-Coco, Giuseppe Avvisati, Marco Vignetti, et al.
Nature Communications|April 8, 2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasmsWilliam Tapper, Amy V Jones, Robert Kralovics, et al.
Leukemia|January 13, 2019
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroupsDetlef Haase, Kristen E Stevenson, Donna Neuberg, et al.
Leukemia & Lymphoma|August 25, 2012
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working GroupArjan A van de Loosdrecht, Robin Ireland, Wolfgang Kern, et al.
Blood|April 30, 2024
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromesMaria Sirenko, Elsa Bernard, Maria Creignou, et al.
Pageof 65